LMDX News and Press, LumiraDx Limited From 06/08/22

Gainers: DBV Technologies (DBVT) +21%. Rubius Therapeutics (RUBY) +20%. Annovis Bio (ANVS) +17%. LumiraDx (LMDX) +16%. CTI BioPharma (CTIC) +15%. Losers: Rigel Pharmaceuticals (RIGL) -48%. Cosmos (COSM) -13%. Accelerate Diagnostics (AXDX) ...

London-based LumiraDx (NASDAQ:LMDX) said its Dual-Target SARS-CoV-2 STAR Complete and SARS-CoV-2 & Flu A/B RNA STAR Complete tests received CE marking in the EU. The LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete test allows for the simultaneous detection and differentiation of influ...

LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 &...

Gainers: DBV Technologies  (DBVT) +48%. Biodesix (BDSX) +15%. Intel Corporation (INTC) +7%. Limoneira (LMNR) +6%. Groupon (GRPN) +5%. Losers: Redbox Entertainment (RDBX) -5%. C4 Therapeutics (CCCC) -5%. Kezar Life Sciences (KZR) -5%. Iris Energy Limited (IREN) -5%. LumiraDx Lim...

LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test PR Newswire The LumiraDx NT-proBNP and the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays...

London-based LumiraDx (NASDAQ:LMDX) said its HbA1c test for diabetes received CE mark in the EU. The test, which provides results in under seven minutes from sample application, is used for monitoring people with diabetes, and for screening individuals who may be at risk for develop...

LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform PR Newswire Rapid microfluidic immunofluorescence assay intended for the monitoring of individuals with ...

LumiraDx (NASDAQ:LMDX) said it received the World Health Organization's (WHO) Emergency Use Listing (EUL) for its rapid COVID-19 antigen assay LumiraDx SARS-CoV-2 Ag Test. The London-based company said that in in studies the test showed 95% positive agreement versus RT-PCR in patien...

LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test PR Newswire LONDON , May 20, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, announced today that its rapid COVID-19 antigen...

LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking PR Newswire Results in just 5 minutes from sample application, aids in fast clinical decision-making at point of care (POC), helping to inform treatment decisions and prevent the further spread of infect...